A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.

Naunyn Schmiedebergs Arch Pharmacol · 2014 · PMC4019832 · PMID 24643470

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In an NSCLC model (H1975, EGFR T790M), combinations of afatinib with a MEK inhibitor ( PD032901 ), a SRC inhibitor (dasatinib) or a PI3K inhibitor (PI-103) showed additive effects on induction of apoptosis, although this did not reach statistical significance (Sos et al. 2010 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.